AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01441323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
Study NCT01441323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training & Nutrition
Description: Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
Study NCT02133092 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
Study NCT04386694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT/sMF
Description: The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
Study NCT04386694 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT/sMF
Description: The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
Study NCT02197091 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02197091 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies
Study NCT04522141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-control intervention
Description: Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
Study NCT04522141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
Study NCT02146391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg Capsules
Study NCT01357252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT01357252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02746276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
Study NCT02812602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
Study NCT02812602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
Study NCT04501991 — intervention group
Intervention type: OTHER
Intervention: antidiabetic treatment
Description: Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
Study NCT03556124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - HD tDCS
Description: Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
Study NCT03556124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - HD tDCS
Description: Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
Study NCT03556124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - Conventional tDCS
Description: Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
Study NCT03556124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - Conventional tDCS
Description: Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
Study NCT01926431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01926431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Study NCT03532529 — intervention group
Intervention type: OTHER
Intervention: not applicable, it is an observational study
Description: not applicable, it is an observational study
Study NCT04742829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INTRAVIT ®
Description: 2 tablets per day morning and evening before meals
Study NCT01410214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
Study NCT01410214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine/cisplatin
Description: In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
Study NCT01870089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCare/PS-NIV Drägerwerk Lübeck Germany
Study NCT02267161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric scales for infants at 3 years of age
Description: WPPSI-III, VINELAND, CBCL, NEPSY
Study NCT04448769 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-SARS-CoV-2 IgT seropositivity
Description: Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM).
Study NCT04247295 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Cast
Description: Application of a traditional cast
Study NCT04247295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Woodcast
Description: Application of a woodcast
Study NCT03833414 — intervention group
Intervention type: PROCEDURE
Intervention: triceps lifting and olecranon osteotomy approaches
Description: two different surgical approaches for distal humerus fracture
Study NCT04360837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment
Description: incremental and decremental positive end-expiratory pressure alveolar recruitment
Study NCT04057846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided transgastric drainage
Description: Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
Study NCT04057846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS guided transgastric drainage
Description: Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
Study NCT04387578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed orthodontic appliance and arch wires
Description: leveling and aligning stages in orthodontics
Study NCT01775605 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Synera
Description: Synera Pain Patch
Study NCT01775605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synera
Description: Synera Pain Patch
Study NCT03311789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor + Gemcitabine + Cisplatin
Description: Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
Study NCT03478033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin capsules, 150mg
Study NCT03478033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin capsules, 150mg
Study NCT03862235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance
Description: The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
Study NCT03862235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
Study NCT03963648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractioned Exhaled Nitrogen Oxide measurements
Description: Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
Study NCT00881816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel plus capecitabine
Description: All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
Study NCT01671917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and exercise program
Description: * 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour
Study NCT01671917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
Study NCT04010591 — intervention group
Intervention type: DEVICE
Intervention: impedance measurement during urodynamic study
Description: Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
Study NCT01628055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Privigen
Description: 10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
Study NCT01628055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours.
Study NCT00470925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I MZINT injection and SPECT imaging
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
Study NCT01459744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training for cardiologists.
Description: Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills.
Study NCT01459744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
Study NCT04992845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Vertebral Body Tethering
Description: The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
Study NCT04408040 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: 200-425mL convalescent plasma donated by patients previously positive for COVID-19
Study NCT03842241 — intervention group
Intervention type: DEVICE
Intervention: Non-custom made foot orthoses
Description: Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
Study NCT02748070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02748070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flonase
Study NCT02748070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonase
Study NCT00285402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-726 Low dose
Study NCT00285402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-726 High dose
Study NCT00285402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-726 Placebo
Study NCT01402882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
Study NCT01402882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
Study NCT01475942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: 4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
Study NCT01475942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: 4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
Study NCT02119559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis by EPISPOT and CellSearch®
Study NCT00689299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Allergenic Extract, Cat Hair
Description: Standardized Cat Hair Allergenic Extract sublingual drops
Study NCT00689299 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sublingual Drops
Study NCT01866280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Normal sleep= sleep 2300-0700
Study NCT01866280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal meals
Description: Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
Study NCT02524847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.
Study NCT02524847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Study NCT01866280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late sleep
Description: Late sleep=sleep at 0230-1030 hours
Study NCT03561038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Franseen Needle
Description: Comparing 2 needles designed for tissue acquisition
Study NCT03561038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fork-tip Needle
Description: Comparing 2 needles designed for tissue acquisition
Study NCT02110914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months.
Study NCT02518802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg per day for 2 years.
Study NCT01920308 — intervention group
Intervention type: DEVICE
Intervention: 5 mm Bard LifeStent Vascular Stent
Description: The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.